tulstrup

Soren Tulstrup to lead Shire’s genetics franchise

pharmafile | July 31, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Shire has appointed Soren Tulstrup as its new senior vice president and franchise lead, MPS (mucopolysaccharides) for its human genetic therapies (HGT) business.

In this role, Tulstrup will be responsible for developing global strategy for the MPS franchise, which includes both commercial and pipeline products, and will play a key role in strategic decisions made about the company’s growing rare disease portfolio.

He will report to Sylvie Grégoire, president of Shire HGT, and will be based in Shire’s office in Nyon, Switzerland.

Advertisement

Tulstrup is the former president and chief executive of Santaris Pharma, where he led business development efforts resulting in four major partnership agreements, including an ongoing collaboration with Shire.

Before joining Santaris Pharma, Tulstrup spent over a decade at Merck & Co, both in Europe and the US, in roles of increasing responsibility.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content